Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 7/2017

01-07-2017 | Original Article

Reduced bone mass and preserved marrow adipose tissue in patients with inflammatory bowel diseases in long-term remission

Authors: C. M. Bastos, I. M. Araújo, M. H. Nogueira-Barbosa, C. E. G. Salmon, F. J. A. de Paula, L. E. A. Troncon

Published in: Osteoporosis International | Issue 7/2017

Login to get access

Abstract

Summary

Bone marrow adipose tissue has not been studied in patients with inactive inflammatory bowel disease. We found that these patients have preserved marrow adiposity even with low bone mass. Factors involved in bone loss in active disease may have long-lasting effects but do not seem to affect bone marrow adiposity.

Introduction

Reduced bone mass is known to occur at varying prevalence in patients with inflammatory bowel diseases (IBD) because of inflammation, malnutrition, and steroid therapy. Osteoporosis may develop in these patients as the result of an imbalanced relationship between osteoblasts and adipocytes in bone marrow. This study aimed to evaluate for the first time bone mass and bone marrow adipose tissue (BMAT) in a particular subgroup of IBD patients characterized by long-term, steroid-free remission.

Methods

Patients with Crohn’s disease (CD; N = 21) and ulcerative colitis (UC; N = 15) and controls (C; N = 65) underwent dual X-ray energy absorptiometry and nuclear magnetic resonance spectroscopy of the L3 lumbar vertebra for BMAT assessment.

Results

Both the CD and UC subgroups showed significantly higher proportions of patients than controls with Z-score ≤−2.0 at L1–L4 (C 1.54%; CD 19.05%; UC 20%; p = 0.02), but not at other sites. The proportions of CD patients with a T-score ˂−1.0 at the femoral neck (C 18.46%; CD 47.62%; p = 0.02) and total hip (C 16.92%; CD 42.86%; p = 0.03) were significantly higher than among controls. There were no statistically significant differences between IBD patients and controls regarding BMAT at L3 (C 28.62 ± 8.15%; CD 29.81 ± 6.90%; UC 27.35 ± 9.80%; p = 0.67).

Conclusions

IBD patients in long-term, steroid-free remission may have a low bone mass in spite of preserved BMAT. These findings confirm the heterogeneity of bone disorders in IBD and may indicate that factors involved in bone loss in active disease may have long-lasting effects on these patients.
Literature
1.
2.
Ghosh S, Cowen S, Hannan WJ et al (1994) Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 107:1031–1039CrossRefPubMed
3.
Tilg H, Moschen AR, Kaser A et al (2008) Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57:684–694CrossRefPubMed
4.
Jahnsen J, Falch JA, Aadland E et al (1997) Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut 40:313–319CrossRefPubMedPubMedCentral
5.
Ardizzone S, Bollani S, Bettica P et al (2000) Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis. J Intern Med 247:63–70CrossRefPubMed
6.
Silvennoinen A, Karttunen TJ, Niemelã SE et al (1995) A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 37:71–76CrossRefPubMedPubMedCentral
7.
Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4:368–381CrossRefPubMed
8.
Pigot F, Roux C, Chaussade S et al (1992) Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 37:1396–1403CrossRefPubMed
9.
Roux C, Abitbol V, Chaussade S et al (1995) Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 5:156–160CrossRefPubMed
10.
Targownik LE, Bernstein CN, Leslie WD (2014) Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol 30:168–174CrossRefPubMed
11.
Pietschmann P, Resch H, Woloszczuk W et al (1990) A circadian rhythm of serum osteocalcin levels in postmenopausal osteoporosis. Eur J Clin Investig 20:310–312CrossRef
12.
Yavropoulou MP, Tomos K, Tsekmekidou X et al (2011) Response of biochemical markers of bone turnover to oral glucose load in diseases that affect bone metabolism. Eur J Endocrinol 164:1035–1041CrossRefPubMed
13.
Sanchez Cano D, Ruiz-Villaverde R, Olvera Porcel MC et al (2011) Evaluation of bone mineral density, bone turnover markers, the OPG/RANKL system and sTNF-RI in Crohn’s disease. Gastroenterol Hepatol 34:3–9CrossRefPubMed
14.
15.
Bianco P, Riminucci M, Gronthos S et al (2001) Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19:180–192CrossRefPubMed
16.
Li X, Kuo D, Schafer AL et al (2011) Quantification of vertebral bone marrow fat content using 3 tesla MR spectroscopy: reproducibility, vertebral variation, and applications in osteoporosis. J Magn Reson Imaging 33:974–979CrossRefPubMedPubMedCentral
17.
18.
Liu Y, Tang GY, Tang RB et al (2010) Assessment of bone marrow changes in postmenopausal women with varying bone densities: magnetic resonance spectroscopy and diffusion magnetic resonance imaging. Chin Med J 123:1524–1527PubMed
19.
Tang GY, Lv ZW, Tang RB et al (2010) Evaluation of MR spectroscopy and diffusion-weighted MRI in detecting bone marrow changes in postmenopausal women with osteoporosis. Clin Radiol 65:377–381CrossRefPubMed
20.
Silverberg MS, Satsangi J, Ahmad T et al (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5a–36aCrossRefPubMed
21.
Best WR, Becktel JM, Singleton JW et al (1976) Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 70:439–444PubMed
22.
Schousboe JT, Shepherd JA, Bilezikian JP et al (2013) Executive summary of the 2013 ISCD position development conference on bone densitometry. J Clin Densitom 16:455–467CrossRefPubMed
23.
de Paula FJA, de Araújo IM, Carvalho AL et al (2015) The relationship of fat distribution and insulin resistance with lumbar spine bone mass in women. PLoS One 10:e0129764CrossRefPubMedPubMedCentral
24.
25.
Rosen CJ, Bouxsein ML (2006) Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2:35–43CrossRefPubMed
26.
27.
van Hogezand RA, Hamdy NA (2006) Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 243:59–64CrossRef
28.
Bernstein CN, Leslie WD, Leboff MS (2003) AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124:795–841CrossRefPubMed
29.
Compston J, Reid DM, Boisdron J et al (2008) Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 19:1247–1250CrossRefPubMed
30.
Seguro LP, Rosario C, Shoenfeld Y (2013) Long-term complications of past glucocorticoid use. Autoimmun Rev 12:629–632CrossRefPubMed
31.
Cohen A, Shen W, Dempster DW et al (2015) Marrow adiposity assessed on transiliac crest biopsy samples correlates with noninvasive measurement of marrow adiposity by proton magnetic resonance spectroscopy (1H-MRS) at the spine but not the femur. Osteoporos Int 26:2471–2478CrossRefPubMedPubMedCentral
32.
Bredella MA, Daley SM, Kalra MK et al (2015) Marrow adipose tissue quantification of the lumbar spine by using dual-energy CT and single-voxel 1H MR spectroscopy: a feasibility study. Radiology 277:230–235CrossRefPubMedPubMedCentral
33.
34.
Blebea JS, Houseni M, Torigian DA et al (2007) Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med 37:185–194CrossRefPubMed
35.
Liney GP, Bernard CP, Manton DJ et al (2007) Age, gender, and skeletal variation in bone marrow composition: a preliminary study at 3.0 tesla. J Magn Reson Imaging 26:787–793CrossRefPubMed
36.
Schwartz AV (2015) Marrow fat and bone: review of clinical findings. Front Endocrinol 6:1–6CrossRef
37.
Devlin MJ, Cloutier AM, Thomas NA et al (2010) Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res 25:2078–2088CrossRefPubMedPubMedCentral
38.
Fazeli PK, Bredella MA, Freedman L et al (2012) Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. J Bone Miner Res 27:1864–1871CrossRefPubMedPubMedCentral
39.
de Araújo IM, Salmon CE, Nahas AK et al (2017) Marrow adipose tissue spectrum in obesity and type 2 diabetes mellitus. Eur J Endocrinol 176:21–30CrossRefPubMed
40.
Schett G, Kiechl S, Redlich K et al (2004) Soluble RANKL and risk of nontraumatic fracture. JAMA 291:1108–1113CrossRefPubMed
41.
Vega D, Maalouf NM, Sakhaee K (2007) CLINICAL review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92:4514–4521CrossRefPubMed
42.
Cawthorn WP, Scheller EL, Leaman BS et al (2014) Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab 20:368–375CrossRefPubMedPubMedCentral
43.
Pironi L, Callegari C, Cornia GL et al (1988) Lactose malabsorption in adult patients with Crohn’s disease. Am J Gastroenterol 83:1267–1271PubMed
44.
Dinca M, Fries W, Luisetto G et al (1999) Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 94:1292–1297CrossRefPubMed
45.
Arj A, Razavi Zade M, Yavari M et al (2016) Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis 19:864–868CrossRefPubMed
Metadata
Title
Reduced bone mass and preserved marrow adipose tissue in patients with inflammatory bowel diseases in long-term remission
Authors
C. M. Bastos
I. M. Araújo
M. H. Nogueira-Barbosa
C. E. G. Salmon
F. J. A. de Paula
L. E. A. Troncon
Publication date
01-07-2017
Publisher
Springer London
Published in
Osteoporosis International / Issue 7/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-4014-3

Other articles of this Issue 7/2017

Osteoporosis International 7/2017 Go to the issue

Letter

Increased risk of hip fracture among spouses—evidence of a homogamy effect: response to comments by Minkov

Original Article

Sarcopenia is associated with disability status—results from the KORA-Age study

Original Article

Hip fracture incidence and social deprivation: results from a French ecological study

Original Article

Acute bone changes after lower limb amputation resulting from traumatic injury

Original Article

Evidence that activation of ASIC1a by acidosis increases osteoclast migration and adhesion by modulating integrin/Pyk2/Src signaling pathway

Original Article

Severe hypoglycemia and hip fracture in patients with type 2 diabetes: a nationwide population-based cohort study